

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生 物 科 技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

CLARIFICATION ANNOUNCEMENT IN RELATION TO REVISED PROXY FORM FOR ANNUAL GENERAL MEETING

Reference is made to the proxy form (the “**Original Proxy Form**”) and the supplemental proxy form (the “**Supplemental Proxy Form**”) of Wai Chun Bio-Technology Limited (the “**Company**”) for use by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting (the “**AGM**”) of the Company originally to be held on Wednesday, 22 November 2023 at 10:30a.m. (and at any adjournment thereof), and the revised proxy form (the “**Revised Proxy Form**”) of the Company for use by the Shareholders at the rescheduled AGM to be held on Thursday, 21 December 2023 at 11:00a.m. (and at any adjournment thereof).

The board of directors (the “**Board**”) of the Company would like to clarify that all Original Proxy Form and Supplemental Proxy Form are considered invalid. Shareholders who have already deposited the Original Proxy Form and/or Supplemental Proxy Form should duly complete and deposit the Revised Proxy Form in accordance with the instructions printed thereon not less than 48 hours before the time appointed for holding the rescheduled AGM (i.e. not later than 11:00 a.m. on Tuesday, 19 December 2023 (Hong Kong Time)) or any adjournment or postponement thereof.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Chairman and Chief Executive Officer

Hong Kong, 15 November 2023

As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer), and two independent non-executive directors, namely Ms. Hong Ting and Mr. Wan Bo.